Core Viewpoint - Shanghai Laishi (002252.SZ) has seen its controlling shareholder, Haiyingkang (Qingdao) Medical Technology Co., Ltd., announce a third share buyback plan within six months, reflecting confidence in the company's future development and long-term investment value [1] Group 1: Share Buyback Plans - Haiyingkang plans to increase its stake in Shanghai Laishi by investing between 250 million to 500 million yuan over the next six months, with no price range set for the buyback [1] - The buyback will be funded through self-owned funds and a special loan for share buyback, with the loan covering no more than 90% of the total amount [1] - China Bank has agreed to provide Haiyingkang a special loan of up to 450 million yuan for the share buyback, with a loan term of three years [1] Group 2: Historical Context of Shareholding - This marks the third buyback plan since Haiyingkang acquired control of Shanghai Laishi in early 2024, when it took over 1.766 billion shares, representing 26.58% of the total share capital [1][2] - Haiyingkang has previously completed two rounds of share buybacks, accumulating a total of 72.43 million shares (1.09% of total shares) for approximately 497 million yuan in the first round and 73.04 million shares (1.1% of total shares) for about 500 million yuan in the second round [2] Group 3: Current Shareholding Structure - After the completion of the three rounds of buybacks, Haiyingkang is expected to have invested nearly 1.5 billion yuan in total [3] - Currently, Haiyingkang directly holds 1.475 billion shares (22.21% of total shares) and controls an additional 437 million shares (6.58% of total shares) through voting rights entrusted by Grifols, S.A., totaling 1.912 billion shares (28.80% of total shares) [3] Group 4: Company Performance - Shanghai Laishi is one of China's largest blood product manufacturers, operating 44 plasma collection stations across 11 provinces [3] - In 2024, the company achieved a record plasma collection volume exceeding 1,600 tons, with total revenue of 8.176 billion yuan, a year-on-year increase of 2.67%, and a net profit of 2.193 billion yuan, reflecting a year-on-year growth of 23.25% [3]

粗略计算，上述两次增持已耗资10亿元。若叠加本次计划增持最高金额，海盈康对上海莱士累计增持金 额将达15亿元。 截至2025年5月19日，海盈康直接持有上海莱士14.75亿股股份，占公司总股本的22.21%，并通过接受基 立福所持上海莱士股份表决权委托的方式支配上海莱士6.58%的表决权，海盈康合计控制上海莱士19.12 亿股股份所对应的表决权，是上海莱士的控股股东，实际控制人为海尔集团。 实际上，海尔集团一直看好上海莱士的发展。去年年底，海尔集团曾计划通过旗下海尔生物以发行A股 换股方式吸收合并市值远超自身的上海莱士，试图实现强强联合。不过，两周后双方就宣布交易终止， 原因是 "未能形成各方认可的具体方案"。 5月21日晚，上海莱士发布公告称，公司控股股东海盈康（青岛）医疗科技有限公司（简称"海盈康"） 计划自公告披露日起6个月内，以集中竞价交易方式增持公司股份，增持金额不低于2.5亿元且不超过5 亿元。 根据公告，本次增持资金主要来源于海盈康自有资金及股份增持专项贷款，其中，专项贷款资金占比不 超过90%，中国银行青岛市分行已向海盈康提供不超过4.5亿元、期限3年的股票增持专项贷款支持。 或受消息提振影响 ...

Core Viewpoint - The controlling shareholder of Shanghai Laishi Blood Products Co., Ltd., Haiyingkang (Qingdao) Medical Technology Co., Ltd., plans to increase its shareholding in the company to enhance investor confidence and demonstrate long-term investment value [3][6]. Group 1: Shareholding Details - Haiyingkang currently holds 1,474,578,052 shares, accounting for 22.21% of the total share capital of Shanghai Laishi [3][4]. - Including the voting rights of 437,069,656 shares held by Grifols, S.A., Haiyingkang controls a total of 1,911,647,708 shares, representing 28.80% of the total share capital [3][4]. Group 2: Increase Plan Details - The planned increase in shareholding amounts to no less than RMB 250 million and no more than RMB 500 million, excluding transaction costs [6][7]. - The increase will be executed through centralized bidding without a specified price range, based on the reasonable judgment of the stock's value [6][8]. - The implementation period for this plan is within six months from the announcement date, with provisions for delays if the stock is suspended [7][9]. Group 3: Funding and Commitment - The funding for the share purchase will come from self-owned funds and a special loan, with the loan portion not exceeding 90% of the total [7][9]. - A loan commitment of up to RMB 450 million has been issued by Bank of China to support this share purchase [7][9]. - Haiyingkang commits to completing the share increase within the specified period and will not reduce its holdings during this time [9].

Group 1 - The State Financial Supervision Administration and seven other departments issued measures to support financing for small and micro enterprises, emphasizing the establishment of a coordination mechanism for financing support [1] - The measures include conducting extensive visits to small and micro enterprises to assess their operational status and financing needs, facilitating direct access to bank credit [1] - There is a focus on addressing the operational difficulties faced by small and micro enterprises and encouraging support for key sectors such as foreign trade, private enterprises, technology, and consumption [1] Group 2 - In May 2025, a total of 130 domestic online games were approved by the National Press and Publication Administration [2] Group 3 - The State Council announced the removal of Wang Jianjun from the position of Vice Chairman of the China Securities Regulatory Commission [3] Group 4 - The Shanghai Municipal Government issued a plan to boost consumption, which includes measures to promote reasonable income growth and improve wage distribution mechanisms [4] - The plan aims to enhance the minimum wage adjustment mechanism and support the development of the rural economy and new business models [4] Group 5 - Shanghai is accelerating the introduction of childcare subsidies and maternity social security subsidies as part of its efforts to build a family-friendly society [5] - The city plans to explore increasing parental leave and spouse's paternity leave while enhancing the quality of public kindergartens [5] Group 6 - The Ministry of Foreign Affairs stated that China has the capability and confidence to handle external risks, including tariff wars, as evidenced by a 2.4% year-on-year increase in total goods import and export in the first four months of the year [6] - Exports grew by 7.5%, indicating strong international competitiveness despite high tariff barriers [6] Group 7 - The Ministry of Foreign Affairs expressed strong opposition to the EU's unilateral sanctions against Chinese companies, emphasizing the need for fair trade practices [8] - The ministry highlighted that normal business interactions between Chinese and Russian companies should not be disrupted by these sanctions [8] Group 8 - The Dalian Commodity Exchange announced trading arrangements for the Dragon Boat Festival period, with a market closure from May 31 to June 2, 2025, and a return to normal trading on June 3 [9] Group 9 - Heng Rui Pharmaceutical set the issuance price for its H-shares at HKD 44.05 per share [11] - Xinyuan Technology plans to issue H-shares and list on the Hong Kong Stock Exchange [11] - The company Guokai Microelectronics is planning a major asset restructuring, leading to a suspension of its stock from May 22 [11]

Group 1 - The Shanghai Composite Index increased by 0.21%, while the CSI Shanghai Technology Leading Index reported a value of 1547.52 points [1] - The CSI Shanghai Technology Leading Index has risen by 3.22% in the past month, decreased by 6.91% over the last three months, and increased by 5.45% year-to-date [2] - The index consists of 50 listed companies in Shanghai with strong profitability, growth potential, and high R&D investment, reflecting the overall performance of the technology sector in the region [2] Group 2 - The top ten weighted companies in the CSI Shanghai Technology Leading Index include WuXi AppTec (10.44%), SMIC (9.61%), and Will Semiconductor (7.75%) [2] - The index's holdings are primarily from the Shanghai Stock Exchange (77.27%) and the Shenzhen Stock Exchange (22.73%) [2] - The industry composition of the index shows that Information Technology accounts for 48.25%, Healthcare for 26.04%, Communication Services for 14.06%, Industry for 10.46%, and Materials for 1.19% [2] Group 3 - The index samples are adjusted semi-annually, with adjustments occurring on the next trading day after the second Friday of June and December [3] - If a sample company ranks in the top two by total market capitalization within its industry, it is prioritized for retention during adjustments [3] - The weight factors are adjusted in line with the sample adjustments, and special circumstances may lead to temporary adjustments [3]

Key Points - Vanke A has signed a supplementary agreement with Shenzhen Metro Group for a loan of up to 4.2 billion yuan, with a pledge of up to 6 billion yuan in shares of its subsidiary, Wanwu Cloud [3] - Heng Rui Pharmaceutical has set the final price for its H-share issuance at 44.05 HKD per share, with plans to list on the Hong Kong Stock Exchange on May 23, 2025 [4] - Wan Dong Medical has elected Ma Chibing as the new chairman after Hu Ziqiang resigned from the position [5] - Tianqi Mould has confirmed that there are no undisclosed significant matters amid ongoing major asset restructuring [6] - Zhejiang Rongtai plans to invest 20 million yuan to establish a wholly-owned subsidiary focused on intelligent robotics [7] - ST Mingcheng intends to publicly transfer 45% of its subsidiary, Time Media, which will no longer be included in the consolidated financial statements [8] - Shanghai Xiba plans to purchase patent assets for 2 million yuan and 500,000 yuan, and establish subsidiaries to promote the commercialization of new technologies [9] - Jushen Co. has received a total of 95.7 million yuan in dividends from its six wholly-owned subsidiaries [10] - ST Asia Pacific has confirmed no undisclosed significant matters or ongoing major plans [11] - Tianrong Tianyu's controlling shareholder's agreement will not be renewed after its expiration [12] - Wangzi New Materials has stated that its energy storage capacitor business is minimal and will not significantly impact its performance [13] - Nanjing Port has clarified that its foreign trade container business does not have direct routes to the U.S. [14] - Jinlongyu has indicated that its solid-state battery business has not yet formed stable long-term revenue [15] - Tianzhihang's subsidiary plans to raise capital by introducing investors [16] - State Grid Information plans to acquire 100% of Yili Technology for 1.853 billion yuan, enhancing its revenue and profit [17] - ST Nongsang will remove its delisting risk warning starting May 23 [18] - Yipin Hong has stated that its innovative drug AR882 has not yet been launched and will not significantly impact recent performance [19] - Huanrui Century has announced a performance compensation plan requiring original shareholders to compensate 116 million shares [20] - Huaren Health plans to acquire stakes in three pharmaceutical chain companies for a total of 3.282 billion yuan [21][22] - Hongming Co. is planning to acquire 83% of Shenzhen Chisu for 1.51 billion yuan [23] - Aishida intends to acquire an additional 7% stake in its subsidiary Qianjiang Robot for 13.09 million yuan [24] - Dasheng Intelligent has signed a contract worth 11.5 million yuan for a high-efficiency machine room project [25] - Jinggu Co. has received a notice to supply wheels for a major global automaker, with expected sales of approximately 158 million USD over ten years [26] - Pingzhi Information has signed a framework agreement with China Mobile for antenna products worth up to 13.01 million yuan [27] - Shanghai Laishi's controlling shareholder plans to increase its stake by 250 million to 500 million yuan [28] - Qixia Construction's shareholder plans to reduce its stake by up to 3% [29] - Sichuan Gold's major shareholders plan to reduce their stakes by up to 5.5% [30] - Qingyun Technology's shareholders plan to reduce their stakes by up to 4.5% [31] - Rhein Biological's directors plan to reduce their stakes by up to 0.14% [32] - Qingmu Technology's shareholder plans to reduce its stake by up to 3% [33] - Sanrenxing's employee shareholding platform plans to reduce its stake by up to 3% [34][35] - Juzhi Technology's director plans to reduce his stake by up to 40,000 shares [36] - Jingwang Electronics' major shareholders plan to reduce their stakes by up to 2.99% [37] - Jujiao Co. plans to reduce its stake by up to 2.6% [38] - Xiyu Tourism's major shareholder plans to reduce its stake by up to 3% [39]

证券代码：002252 证券简称：上海莱士 公告编号：2025-043 上海莱士血液制品股份有限公司 关于控股股东增持股份计划的公告 公司控股股东海盈康（青岛）医疗科技有限公司保证向本公司提 供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大 遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供 的信息一致。 特别提示： 上海莱士血液制品股份有限公司（以下简称"上海莱士"或"公司"）控股股东 海盈康（青岛）医疗科技有限公司（以下简称"海盈康"）基于对公司未来发展的 信心和长期投资价值的认同，增强投资者信心，计划自本公告披露之日起6个月 内（除法律、法规及深圳证券交易所业务规则等有关规定不准增持公司股票的期 间之外），通过深圳证券交易所交易系统以集中竞价交易方式增持公司股份。本 次计划增持总金额不低于人民币25,000万元，且不超过人民币50,000万元（均含 本数且不包含交易费用）（以下简称"本次增持计划"）。本次增持计划不设置价 格区间。 公司于近日收到控股股东海盈康《关于增持上海莱士血液制品股份有限公司 股份计划的告知函》，现将相关情况公告如下： 一、计划增持主体的基本情况 1、增持主 ...

证券代码：002252 证券简称：上海莱士 公告编号：2025-042 上海莱士血液制品股份有限公司 2024 年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会不存在增加、变更、否决提案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议； 3、本次会议提案涉及股东大会特别决议事项，按照《公司章程》规定，本次特 别决议事项需经出席会议股东（包括股东代理人）所持表决权 3/4 以上表决同意后方 可通过。 一、会议召开和出席情况 （一）会议召开情况 1、现场会议召开时间为：2025 年 5 月 20 日（星期二）14:00； 网络投票时间为：2025 年 5 月 20 日（星期二）； 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 5 月 20 日的交易时间，即 9:15－9:25，9:30－11:30，13:00－15:00；通过深圳证券交易所 互联网投票系统投票的具体时间为：2025 年 5 月 20 日 9:15 至 15:00 期间的任意时 间； 2、现场会议召开地点：上海市 ...

北京市金杜（青岛）律师事务所 关于上海莱士血液制品股份有限公司 2024 年度股东大会之 法律意见书 致：上海莱士血液制品股份有限公司 北京市金杜（青岛）律师事务所（以下简称本所）接受上海莱士血液制品 股份有限公司（以下简称公司）委托，根据《中华人民共和国证券法》（以下简 称《证券法》）、《中华人民共和国公司法》（以下简称《公司法》）、中国证券监 督管理委员会《上市公司股东会规则》（以下简称《股东会规则》）等中华人民 共和国境内（以下简称中国境内，为本法律意见书之目的，不包括中国香港特 别行政区、中国澳门特别行政区和中国台湾地区）现行有效的法律、行政法规、 规章、规范性文件和现行有效的《上海莱士血液制品股份有限公司章程》（以下 简称《公司章程》）的有关规定，指派律师出席了公司于 2025 年 5 月 20 日召 开的 2024 年年度股东大会（以下简称本次股东大会），并就本次股东大会相关 事项出具本法律意见书。 1. 经公司 2024 年第三次临时股东大会审议通过的《公司章程》； 2. 公司 2024 年 12 月 28 日刊登于巨潮资讯网及深圳证券交易所网站的《上 海莱士血液制品股份有限公司第六届董事会第六 ...

证券代码：002252 证券简称：上海莱士 公告编号：2025-041 一、增持计划主体的基本情况 上海莱士血液制品股份有限公司 关于控股股东增持公司股份计划实施完成的公告 公司控股股东海盈康（青岛）医疗科技有限公司保证向本公司提 供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大 遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供 的信息一致。 特别提示： 1、增持计划的主要内容：上海莱士血液制品股份有限公司（"上海莱士"、 "公司"）于2025年3月4日披露了《关于控股股东增持股份计划的公告》（公告编 号：2025-020），基于对未来发展的信心和长期投资价值的认同，增强投资者信 心，控股股东海盈康（青岛）医疗科技有限公司（"海盈康"）计划自本次增持计 划公告披露之日起6个月内（除法律、法规及深圳证券交易所业务规则等有关规 定不准增持公司股票的期间之外），通过深圳证券交易所交易系统以集中竞价交 易方式增持公司股份，拟增持金额不低于人民币25,000万元，且不超过人民币 50,000万元（均含本数且不包含交易费用）（"本次增持计划"）。本次增持计 划不设置增持股份价格区间，增持主体基于 ...